

**Table S3. Geometric mean plasma concentrations of ALM201 following subcutaneous administration on Day 18 of treatment cycle 2, 4 and 6 at doses of 10, 20, 40, 80, 100, 160, 200 or 300 mg**

Time after Dosing (h)	ALM201 Plasma Concentration (ng/mL) (Geometric mean (CV%) and range)							
	10 mg	20 mg	40 mg	80 mg	100 mg	160 mg	200 mg	300 mg
<b>Day 18 Cycle 2</b>	(n = 1)	(n = 1)	(n = 1)	(n = 1)	(n = 1)	(n = 1)	(n = 2)	(n = 3)
Pre-dose	NQ	NQ	NQ	NQ	NQ	NQ	NQ	NQ
0.5	158	279	384	394	1060	1380	1210 (NC) 908 – 1620	1990 (42) 1460 – 3150
1	193	394	583	808	1790	1380	1470 (NC) 1010 – 2150	2280 (39) 1810 – 3510
1.5	242	352	565	659	1710	1650	1890 (NC) 1280 – 2790	2380 (55) 1750 – 4130
2	288	386	571	639	1570	1870	1360 (NC) 1240 - 1500	2540 (23) 2110 – 3290
3.5	161	162	347	849	1180	870	911 (NC) 486 – 1710	720 (206)* 169 – 1970
5	NQ	NQ	228	505	535	436	690 (NC) 353 – 1350	485 (58) ** 282 - 825
<b>Day 18 Cycle 4</b>	(n = 1)						(n = 2)	(n = 1)
Pre-dose	NQ	NS	NS	NS	NS	NS	NQ	NQ
0.5	NQ	NS	NS	NS	NS	NS	1080 (NC) 479 – 2430	1670
1	176	NS	NS	NS	NS	NS	1410 (NC) 1100 - 1800	2140
1.5	193	NS	NS	NS	NS	NS	1150 (NC) 734 – 1810	1990
2	171	NS	NS	NS	NS	NS	1500 (NC) 876 – 2580	1990
3.5	157	NS	NS	NS	NS	NS	1310 (NC) 970 -1760	854*
5	NQ	NQ	228	505	535	436	975 (NC) 889 – 1070	387**
<b>Day 18 Cycle 6</b>	(n = 1)							(n = 1)
Pre-dose	NQ	NS	NS	NS	NS	NS	NS	NQ
0.5	171	NS	NS	NS	NS	NS	NS	3150
1	NS	NS	NS	NS	NS	NS	NS	4430
1.5	470	NS	NS	NS	NS	NS	NS	5240
2	403	NS	NS	NS	NS	NS	NS	6830
3.5	179	NS	NS	NS	NS	NS	NS	3600*
5	NS	NS	NS	NS	NS	NS	NS	693**

NS = no sample received; NC = not calculated (n = 2 values); NQ = not quantifiable (less than assay limit of quantification of 100 ng/mL); \*Samples collected at 4.5 hours; \*\*Samples collected at 7.0 hours